Pfizer buys seat at biosimilars table next to Biocon

Biocon will continue to handle the development, manufacture and supply of biosimilar versions of its insulin and insulin analog products, following a deal with Pfizer. Analogs include Recombinant Human Insulin, Glargine, Aspart and Lispro. For its part, Pfizer will commercialize the products globally. Biocon announcement

Suggested Articles

Teva will produce its new migraine drug at a plant in Israel and more news of note.

The shortage of childhood cancer drug vincristine was front and center during the Senate hearing for Stephen Hahn, nominee for FDA commissioner.

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.